Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT03796676) enrolled 285 adults with atopic dermatitis (eczema) across three groups: 96 received a placebo (inactive treatment), 95 received a 100 mg daily dose of PF-04965842 (abrocitinib), and 94 received a 200 mg daily dose. The trial was primarily measuring two things after 12 weeks: how many participants' skin was rated by a doctor as "clear" or "almost clear" on a standard severity scale, and how many participants saw their eczema area and severity score improve by at least 75% from where it started. The reported data shows that at the 12-week mark, 24.5% of placebo participants, 41.6% of the 100 mg group, and 46.2% of the 200 mg group met the doctor-rated "clear or almost clear" skin goal. For the 75% improvement in eczema area and severity, the figures reported were 41.5% (placebo), 68.5% (100 mg), and 72.0% (200 mg). The trial also measured itch severity using a 0–10 self-reported scale, looking at the proportion of participants whose worst itch score improved by at least 4 points. The reported data shows that by week 12, this was achieved by 29.8% of the placebo group, 52.6% of the 100 mg group, and 55.4% of the 200 mg group. A separate symptom diary score (rated 0–10, where higher means worse) showed average reductions from baseline of 2.0 points (placebo), 2.5 points (100 mg), and 2.7 points (200 mg) at week 12. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 42162528) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Eczema Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 12 and 17 years old and weigh at least 40 kg (about 88 lbs)
- You have been diagnosed with atopic dermatitis (eczema) for at least 1 year, and your symptoms are currently moderate to severe based on specific medical scores measuring skin involvement, redness, and itch (confirm with trial site)
Who may not be able to join:
- You have a serious ongoing or long-term health condition, or abnormal lab results, that could make participation risky
- You are not willing to stop your current eczema treatments before the study, or you need to take medications that are not allowed during the study
- You have previously been treated with a type of medication called a JAK inhibitor
- You have another active skin disease or condition affecting your skin, separate from eczema
- You have a medical history that includes low platelet counts, blood clotting problems, cancer, certain infections, disorders affecting the lymph system, or other conditions the study doctor considers relevant (confirm with trial site)
- You are pregnant, breastfeeding, or able to become pregnant but unwilling to use contraception during the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pfizer CT.gov Call Center, Pfizer
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 'Clear' (0) or 'Almost Clear' (1) and ≥2 Points Improvement From Baseline at Week 12; Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response ≥ 75% Improvement From Baseline at Week 12
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.